Owing to their unique properties recombinant E1-deleted adenovirus (Ad) vectors are frequently used in gene therapy protocols. 1 In order to achieve high levels of transgene expression after Ad-mediated transfer, strong constitutive viral promoters, eg the immediate-early promoter from human cytomegalovirus (hCMV-IE), are used in almost all gene therapy vectors. However, the gene expression after Ad-mediated gene transfer is known to be transient due to the generation of humoral and cellular immune responses against the virus-infected cells. 2, 3 In addition, the interaction with cellular regulatory factors might result in low transgene expression. We previously reported that the proinflammatory cytokine tumor necrosis factor alpha (TNF-␣) in vitro either up-or downregulates the reporter gene expression driven by the hCMV-IE promoter, dependent on the cell type and the differentiation stage. 4 Thus in mature macrophages the inhibitory effect dominated. A down-regulation of the hCMV-IE controlled reporter gene expression was also described in endothelial cells and heart muscle cells. 5 for a soluble TNFRp55-Ig chimeric molecule in a syngeneic rat heart transplantation model. Co-application of the reporter construct together with the TNFRp55-Ig chimeric molecule significantly increased the early reporter gene expression after transplantation. Moreover, infiltration of inflammatory cells (T cells, macrophages, NK cells) and production of TNF-␣ in the transplant was markedly reduced.
Our results indicate that: (1) proinflammatory cytokines are involved in down-regulation of reporter gene expression in ischemia/reperfusion injured tissues; and (2) inhibition of TNF-␣ might be a useful tool to increase early gene expression in gene therapy protocols, particularly in transplantation. Gene Therapy (2000) 7, 1238-1243.
vivo the Ad vector by itself induces inflammatory reactions including the release of TNF-␣. 7 Recently it has been shown that the blockade of TNF-␣ increased reporter gene expression after intranasal and intravenous Ad application into the lung and liver, suggesting the in vivo relevance of the cytokine-mediated control of hCMV-IE promoter-driven gene expression. 8, 9 Gene therapy with Ad vectors may be a useful approach in the transplant setting. 10 However, in a rat heart transplant model we observed a delayed reporter gene expression that did not peak before day 7 after transplantation 11 -too late for a significant influence on most of the intragraft events. We have recently observed that intragraft gene transfer of IL-4 prolongs survival of kidney allografts in low responder (LBNF1 to LEW) 12 but not in high responder (WF or DA to LEW) strain combinations. 13 This phenomenon could be explained by the fact that the effects of IL-4 are more potent in low responder than in high responder strain combinations. On the other hand, there is evidence that delayed transgene expression in high responder strain combinations may result in a reduced efficacy of Ad-mediated cytokine gene transfer. What could be the reason for the delayed intragraft expression of transferred genes? Peri-operative ischemia/reperfusion injury induces a strong inflamma-tory response that may down-regulate the hCMV-IE controlled gene expression. 14, 15 This study demonstrates that the parallel application of an Ad encoding for the TNFRp55-Ig construct reduced the early intragraft cellular infiltration and cytokine expression, resulting in improved intragraft Ad-mediated reporter gene expression. To our knowledge, ischemia/reperfusion injury has not been treated by the administration of recombinant TNFRp55-Ig so far. Our data underline the key role of TNF-␣ in the early post-transplant control of gene expression.
Recently, we have observed that Ad-mediated transgene expression was already detectable 24 h after intratracheal or intravenous application and reached peak levels at day 3. 19, 20 In contrast, reporter gene expression in syngeneic heart transplants was delayed. The number of cells positive for expression of E. coli ␤-galactosidase (␤-gal) did not reach peak levels before day 7.
11 Similar results could be obtained by quantification of ␤-gal expression using the ONPG assay ( Figure 1 ). Since it is known that proinflammatory cytokines are up-regulated within a few hours in transplanted organs due to ischemia/reperfusion injury 14, 15 we wondered whether proinflammatory cytokines, eg TNF-␣, might be involved in the delay of reporter gene expression in rat syngeneic heart grafts compared with reporter gene expression after intratracheal application. To address this question a recombinant Ad expressing a soluble TNFRp55-Ig construct with the capacity to block completely TNF-␣ and lymphotoxin-␣ (AdTNFRp55-Ig, TNF inhibitor) has been used in all subsequent experiments. Rat hearts were injected either with 5 × 10 9 plaque-forming units (p.f.u.) of the reporter construct Ad␤-gal alone or together with 5 × 10 9 p.f.u. of AdTNFRp55-Ig and reporter gene expression was determined by ONPG assay at different time-points. As shown in Figure 1 , reporter gene expression was significantly elevated as early as on day 3 after transplantation when the TNF inhibitor was coinjected together with the Ad␤-gal construct. The increased transgene expression in hearts following blockade of TNF-␣ was still detectable at day 7. In order to address the question if the rise in reporter gene expression is a result of hCMV-IE promoter-dependent increase of transcription and not caused by a decrease of Ad␤-gal-infected cells mediated by innate immune responses we performed in situ X-gal staining of tissue sections ( Figure 2 ). We could clearly show that the increase in reporter gene expression is not due to a reduced elimination of Ad-infected cells. As shown in Figure 2 , there is no significant difference in the number of Ad-infected cells in Ad␤-gal or Ad␤-gal/TNFRp55-Ig treated hearts on day 3 and day 7. To understand the mechanism of these effects, we analyzed the infiltration of inflammatory cells in the graft after Ad-mediated gene transfer. We could show that the co-application of AdTNFRp55-Ig led to a significantly reduced early infiltration of CD8 ished TNF-␣ mRNA expression in syngeneic heart grafts on day 3 and a two-fold reduction of TNF-␣ mRNA expression on day 7 after transplantation ( Figure 6) .
Here, we have demonstrated that the inhibition of the proinflammatory cytokine TNF-␣ resulted: (1) an early increase in reporter gene expression after Ad-mediated gene transfer; (2) a reduced infiltration of inflammatory cells (T cells, monocytes/macrophages, NK cells); and (3) a reduced production of proinflammatory cytokines by the infiltrating cells themselves.
One of the major obstacles in gene therapy protocols, particularly in Ad-based approaches, is the transient expression of a given therapeutic gene due to the generation of an immune response against virus-infected cells. 3, 4 However, this is probably not the most limiting factor of gene therapy in the transplant setting since therapeutic applications, eg prevention of ischemia/ reperfusion injury, should only require a transient expression of the therapeutic gene product. Several data suggest that elimination of the Ad-transduced cells by the specific antiviral immune response is not the only reason for the down-regulation of the gene of interest expression. Our results presented here and the results of other groups 5, 6, 7, 21 indicate that the viral promoters used in almost all gene therapy vectors owing to their strong transcriptional activity in vitro are sensitive to cytokines during inflammatory responses in vivo. This might be a major hindrance for the application of conventional gene therapy vectors where transgene expression is controlled by the hCMV-IE promoter. The mechanisms of how these cytokines down-regulate promoter activity are still poorly understood. TNF-␣ strongly influences the hCMV-IE promoter. Depending on the cell lineage and its differentiation stage, TNF-␣ can both up-or downregulate the promoter activity. 5 Recently, we demonstrated that the stimulation of the hCMV-IE promoter by TNF-␣ is realized via activation of NFB that binds to 18 bp repeats within the promoter region. Blockade of NFB activation or mutation of the binding sites in those 18 bp repeats abolished the stimulatory properties in bone marrow-derived monocyte/macrophage progenitor cells. 22, 23 However, in several cell lineages (eg mature macrophages) TNF-␣ inhibits the hCMV-IE promoter activity, although NFB activation is also observed in those cells, 5, 23 suggesting the involvement of negative regulatory elements in response to TNF-␣ in several cell types. Our data presented here and the observations by others 5, 7 suggest that this inhibitory effect by TNF-␣ on the hCMV-IE promoter activity seems to play a major role following in vivo gene transfer.
u.)-treated hearts were analyzed (days 3, 7, 28) for infiltration of T cells and NK cells using an alkaline phosphatase antialkaline phosphatase (APAAP) technique. Six-m thick cryostat sections of the apical part were fixed in acetone for 10 min at room temperature. To block nonspecific antibody binding, slides were incubated in 20% rabbit serum/FACS-buffer (0.1% NaN 3 , 1% FCS in PBS) for 20 min at room temperature. Sections were incubated with mouse antibodies against rat TCR ␣/␤ (R73), CD8-␤-chain (34.1, both hybridomas kindly provided by T Hü nig,
Recently, it has been shown that the blockade of TNF-␣ by the application of a soluble TNF-binding protein increased transgene expression after intranasal and intra- venous gene transfer. 9 However, the half-life of proteins injected in either the lung or blood might be rather low and systemic application may lead to undesired sideeffects. In addition, Zhang et al 8 pretreated recipients with the TNF-binding protein before application of the reporter construct. It has been demonstrated that intravenous application of a recombinant Ad expressing a soluble TNFRp55-Ig chimeric molecule leads to systemic distribution of TNFRp55-Ig and subsequent neutralization of TNF-␣ and lymphotoxin-␣, which in turn may render the recipient susceptible to bacterial infections. 16 However, the local inhibition of TNF-␣ by simultaneous ex vivo application of both a recombinant Ad expressing a soluble TNFRp55-Ig chimeric molecule and an Ad-conGene Therapy struct expressing a therapeutic gene may open the field for new strategies in gene therapy protocols. Our data indicate that treatment with the TNF inhibitor could be performed at the same time when the gene of interest is applied rather than a pretreatment of the recipient before the application of the therapeutic gene. Despite local application of AdTNFRp55-Ig significant amounts of the TNFRp55-Ig fusion protein (some ng/ml) could be detected in the periphery (data not shown). However, the levels of TNFRp55-Ig fusion protein were lower than after application of the same Ad concentration into the liver. In addition, for systemic application (i.v.) of TNFRp55-Ig (w/o gene therapy), Zhang et al 8 used 100 ng per mouse of TNFRp55-Ig for their approach. We cannot fully exclude the possibility that systemic distribution of TNFRp55-Ig may affect the results we have observed with regard to prevention of ischemia/ reperfusion injury, however, we believe that it is rather unlikely. The major advantage of the local application of gene therapy vectors compared with systemic administration is that local application may only lead to moderate inflammatory responses against Ad-infected cells or tissues. In addition, these data indicate that the adenovirus dose for intragraft expression of relatively stable therapeutic proteins, eg TNFRp55-Ig, could be reduced thereby maintaining the same local effects while reducing the amount of soluble TNFRp55-Ig in the periphery.
We could demonstrate that down-regulation of reporter gene expression was significantly inhibited after co-injection of the TNF inhibitor in syngeneic rat hearts followed by heterotopic transplantation (see Figure 1 ). This effect was detectable at days 3 and 7 after transplantation and then declined until day 28 after transplantation. Moreover, we could show that the increase in lacZ transcription is not due to a reduced elimination of Adinfected cells. As shown in Figure 2 , there is no significant difference in the number of Ad-infected cells in Ad␤-gal or Ad␤-gal/TNFRp55-Ig-treated hearts on day 3 and day 7. These data indicate that -at least in the syngeneic heart transplant model -the prevention of early antiadenovirus immune responses does not seem to play a role in the increase in ␤-gal expression. Therefore, the increased ␤-gal transcription is mainly a result of inhibiting the TNF-␣-mediated hCMV-IE promoter down-regulation by the soluble TNFRp55-Ig construct. In our syngeneic heart transplant model we did not observe a prolonged transgene expression by blockade of TNF-␣ as shown by Zhang et al 8 and Peng et al 9 in nontransplant models. However, the models and applications were different and this could be the reason for the different results. Since it is well known that proinflammatory cytokines, eg TNF-␣ or interferon-␥, play an important role in the process of graft rejection in the early phase after transplantation, blocking of these cytokines may be very important for the prevention of endothelial cell damage and long-term survival of allografts. The co-application of TNFRp55-Ig together with a therapeutic gene may therefore not only be useful for the prevention of transgene down regulation but also for the reduction of tissue and/or endothelial cell damage mediated by TNF-␣. In addition to the prevention of transgene down-regulation by TNF-␣, the early infiltration of T cells, monocytes/ macrophages and CD8 + T cells was markedly reduced in grafts where TNFRp55-Ig was co-injected (see . This effect is probably mediated by blocking of TNF-␣ which activates endothelial adhesion molecules that allow graft infiltration.
Interestingly, the duration of transgene expression (see Figure 1) was not affected by co-application of the TNF inhibitor which is different to the results of other groups. 8, 9 Our data indicate that the application of TNFRp55-Ig is useful in blocking unspecific immune responses (early phase) quite effectively. However, at least in the syngeneic heart transplant model, specific immune responses against Ad-infected cells (late phase) may not be prevented by blocking TNF-␣ with the TNF inhibitor. The comparable late graft infiltration in controls and TNFR-p55-Ig-treated grafts support this view.
In summary, the prevention of TNF-␣-mediated endothelial activation and tissue damage by local application of a soluble TNF inhibitor might be very useful for the long-term survival of transplanted organs. In addition, down-regulation of transgene expression driven by viral promoters can be inhibited and may lead to higher levels of the therapeutic gene product immediately after transplantation.
